The Challenge: An early-stage drug with strong Phase I results and breakthrough potential—where every month of FDA review time mattered.
How Pharmatech Helped: Built three full-scale Phase I studies to simplify the CMC argument and reduce BLA submission risk.
The Result: Drug achieved breakthrough status. Review time cut by 3–6 months, launching the therapy that much faster.
